Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
51.7
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 March 2026–31 May 2026ConsolidatedJapanese GAAPNet Sales17,034¥ millionYear on year +23.1%Progress 25.8%
Operating profit2,204¥ millionYear on year +51.7%Progress 40.4%
Ordinary income2,192¥ millionYear on year +52.4%Progress 41.0%
Net income attributable to owners of the parent1,486¥ millionYear on year +57.2%Progress 43.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥70.18
Financial position at period-end
Total assets44,492¥ million
of which net assets 19,826 ¥ millionEquity ratio 43.8%vs. prior year-end +2.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueCreative (Japan) ¥10,564 million (YoY +114.2%), Creative (Korea) ¥802 million (YoY +105.2%), Medical Field ¥2,239 million (YoY +115.6%), Accounting and legal ¥612 million (YoY +101.1%), CRES ¥1,745 million, Other Businesses ¥1,069 million (YoY +84.1%)
Segment profitCreative (Japan) ¥818 million (YoY +123.1%), Creative (Korea) ¥-18 million, Medical Field ¥1,038 million (YoY +128.9%), Accounting and legal ¥45 million (YoY +94.3%), CRES ¥310 million, Other Businesses ¥10 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥66,000 million (YoY +7.5%)
Operating profit¥5,450 million (YoY +10.4%)
Ordinary income¥5,350 million (YoY +10.9%)
Net income¥3,450 million (YoY -16.0%)
Revision to Earnings ForecastNet Sales Not disclosed → ¥66,000 million / Operating profit Not disclosed → ¥5,450 million / Ordinary income Not disclosed → ¥5,350 million / Net income Not disclosed → ¥3,450 million
Annual Dividend Forecast50.00 yen and sen → 51.00 yen and sen
Factors Behind Changes in Business Performance
Performance progressed steadily, primarily in the key Creative (Japan) and Medical segments, and performance in the Takahashi Shoten Group also progressed steadily.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew: — companies; excluded: — companies (company names not stated)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥5,157 thousand, Gain on sale of shares in an affiliated company ¥1,763 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand, Loss related to office relocation ¥7,096 thousand
Depreciation and amortization¥168,874 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (no attendees specified)
Issued Shares at Period-End23,009,000 shares
Treasury Shares at Period-End1,833,769 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2026–31 May 2026 |
| Net Sales | ¥17,034 million (YoY +23.1%) |
| Operating profit | ¥2,204 million (YoY +51.7%) |
| Ordinary income | ¥2,192 million (YoY +52.4%) |
| Profit attributable to owners of the parent | ¥1,486 million (YoY +57.2%) |
| Net income per share | ¥70.18 |
| Equity ratio | End of the current fiscal period 43.8% / End of previous period 40.9% |
| Total assets | ¥44,492 million |
| Net assets | ¥19,826 million |
| Full-year earnings forecast | Net Sales ¥66,000 million (YoY +7.5%) / Operating profit ¥5,450 million (YoY +10.4%) / Ordinary income ¥5,350 million (YoY +10.9%) / Net income ¥3,450 million (YoY -16.0%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥66,000 million / Operating profit Not disclosed → ¥5,450 million / Ordinary income Not disclosed → ¥5,350 million / Net income Not disclosed → ¥3,450 million |
| Annual Dividend Forecast | 50.00 yen and sen → 51.00 yen and sen |
| Segment revenue | Creative (Japan) ¥10,564 million (YoY +114.2%), Creative (Korea) ¥802 million (YoY +105.2%), Medical Field ¥2,239 million (YoY +115.6%), Accounting and legal ¥612 million (YoY +101.1%), CRES ¥1,745 million, Other Businesses ¥1,069 million (YoY +84.1%) |
| Segment profit | Creative (Japan) ¥818 million (YoY +123.1%), Creative (Korea) ¥-18 million, Medical Field ¥1,038 million (YoY +128.9%), Accounting and legal ¥45 million (YoY +94.3%), CRES ¥310 million, Other Businesses ¥10 million |
| Depreciation and amortization | ¥168,874 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥5,157 thousand, Gain on sale of shares in an affiliated company ¥1,763 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand, Loss related to office relocation ¥7,096 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New: — companies; excluded: — companies (company names not stated) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (no attendees specified) |
| Issued Shares at Period-End | 23,009,000 shares |
| Treasury Shares at Period-End | 1,833,769 shares |
| Factors Behind Changes in Business Performance | Performance progressed steadily, primarily in the key Creative (Japan) and Medical segments, and performance in the Takahashi Shoten Group also progressed steadily. |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Performance in the key Creative (Japan) and Medical segments progressed steadily, as did the Takahashi Shoten Group, which became a consolidated subsidiary in the previous fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.